Tandem Diabetes Care (TNDM) to Release Quarterly Earnings on Wednesday

Tandem Diabetes Care (NASDAQ:TNDM) will likely be announcing its earnings results after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $251.39 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Tandem Diabetes Care Trading Down 3.5 %

Shares of TNDM opened at $31.00 on Monday. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care has a 12-month low of $24.42 and a 12-month high of $53.69. The firm has a 50-day moving average price of $35.48 and a 200 day moving average price of $36.70. The firm has a market capitalization of $2.04 billion, a P/E ratio of -16.06 and a beta of 1.32.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on TNDM shares. Morgan Stanley raised shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 price objective for the company in a report on Monday, December 2nd. Canaccord Genuity Group lowered their target price on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Sanford C. Bernstein started coverage on shares of Tandem Diabetes Care in a research note on Wednesday, November 6th. They set an “outperform” rating and a $42.00 target price for the company. Barclays increased their target price on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. Finally, Robert W. Baird lowered their target price on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating for the company in a research note on Thursday, November 7th. Four equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $53.81.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.